People searching “TB-500 side effects” usually want a straight answer: what can this peptide do to me, how likely is it, and how bad can it get? Here is the honest headline: there are essentially no published human safety studies of TB-500 itself. The reassuring “well tolerated” claims that circulate online come from clinical trials of a different, longer molecule — full-length thymosin β4 — given short-term under medical supervision, not from the TB-500 sold as a research chemical. On top of that, laboratory research flags a real theoretical cancer-promotion concern, and the long-term effects of self-injecting TB-500 are simply unknown. This page is a research-use-only (RUO) reference and is not medical advice.
Chemistry first, because it drives everything else. Independent analyses of commercial “TB-500” products show the active ingredient is not whole thymosin β4 but a synthetic, N-terminally acetylated fragment of it — the 17–23 actin-binding region, Ac-LKKTETQ (Esposito et al., 2012; Ho et al., 2012). So when a seller cites “thymosin β4 clinical trials” as proof TB-500 is safe, that is a substitution the evidence does not support.
Documented side effects
The table below separates clinical (human-trial) findings from preclinical (lab/animal) and analytical evidence. Every human tolerability figure comes from trials of full-length thymosin β4, not the TB-500 fragment.
| Effect | Frequency / severity | Evidence source (type) |
|---|---|---|
| General / infusion-related adverse events | Infrequent, mild-to-moderate; no serious adverse events or dose-limiting toxicity in short-term dosing | Clinical — Ruff 2010; Wang 2021 (full-length Tβ4, IV, ≤14 days) |
| Anti-drug antibodies (immunogenicity) | Built into trial protocols as a monitored risk; peptides can provoke immune responses | Clinical — Wang 2021; trial NCT04555850 |
| Tumour-promoting activity (angiogenesis, anti-apoptosis, cell migration/EMT) | Serious but theoretical; observed in cell/tumour models, not reported as a human-trial side effect | Preclinical — Smart 2007; Xing 2021; Jin 2025 |
| Long-term / chronic self-injection effects | Unknown — no human data exist | Evidence gap (none identified) |
In plain terms: in short Phase 1 dosing of full-length thymosin β4, adverse events were “infrequent, and mild or moderate,” with no serious adverse events and no dose-limiting toxicity (Ruff et al., 2010, DOI; Wang et al., 2021, DOI; indexed in PubMed). That is genuinely reassuring for that molecule, that route, and that timeframe — and it tells us very little about weeks-to-months of unregulated TB-500 self-injection.
The serious signal is preclinical. The same properties that make thymosin β4 attractive for tissue repair — promoting angiogenesis, cell migration and survival while suppressing programmed cell death — are also mechanisms that can favour tumour growth. Reviews and mechanistic work describe Tβ4 driving angiogenesis and tumour progression (Smart et al., 2007; Xing et al., 2021), and a 2025 study reported that Tβ4 promotes breast-cancer proliferation, migration, EMT and angiogenesis, with high expression linked to worse clinical outcomes (Jin et al., 2025). This is a laboratory concern, not a confirmed human side effect — but it is exactly the kind of risk that “no long-term human data” leaves completely unmonitored.
Who is at higher risk / contraindications
- Anyone with active or prior cancer, or a strong family history: the documented pro-angiogenic and anti-apoptotic mechanisms are a theoretical concern with no human safety data to offset it (Smart 2007; Xing 2021; Jin 2025).
- Pregnant or breastfeeding individuals: uniformly excluded from thymosin β4 trials; no safety data.
- People with peptide/protein hypersensitivity: immunogenicity (anti-drug antibodies) is a recognised, protocol-monitored risk (Wang 2021).
- Tested / competitive athletes: TB-500 and thymosin β4 are prohibited in sport by WADA and the equine authorities FEI and IFHA (Delcourt et al., 2024). Use risks sanctions independent of any health effect.
- Anyone who cannot verify product identity and purity: TB-500 circulates as non-authorised products sold online (Delcourt 2024), so contamination and mislabelling are unquantified additional risks.
What we do NOT know
For a “research peptide” like TB-500, the gaps are not a footnote — they are the main risk. Absence of evidence here means absence of safety monitoring, not evidence of safety.
- There is no completed human safety trial of the TB-500 fragment (Ac-LKKTETQ) itself.
- No data exist on the subcutaneous gray-market dosing and schedules people actually use.
- No long-term or chronic-use human data exist — the reassuring trials lasted days to a few weeks.
- No thymosin β4 product has been approved by the FDA or EMA for any use, despite years of trials (several of which were terminated or withdrawn).
- The cancer question is unanswered in humans: a plausible mechanistic risk with no clinical outcome data either way.
- Drug interactions, effects on people with chronic disease, and product-to-product variability are all uncharacterised.
Dosage & handling reference
Because TB-500 is not an approved medicine, there is no validated human dose — any figures you see are laboratory conventions, not clinical guidance. For reconstitution and unit-conversion documentation used in a research setting only, see our TB-500 dosage reference and the general peptide dosage calculator. These tools exist to document handling accurately; they are not human-use instructions and do not imply the compound is safe or effective.
FAQ
Is TB-500 proven safe in humans?
No. There are no completed human safety trials of the TB-500 fragment. The only human tolerability data are for full-length thymosin β4 — a different molecule — tested short-term under supervision (Ruff 2010; Wang 2021).
Do the thymosin β4 clinical trials apply to TB-500?
Not directly. Commercial TB-500 is a synthetic 17–23 fragment (Ac-LKKTETQ), not whole thymosin β4 (Esposito 2012; Ho 2012), so trial results for the full peptide cannot be assumed to transfer.
Can TB-500 cause cancer?
There is no human evidence either way. However, preclinical studies show thymosin β4 can promote angiogenesis, cell migration and tumour progression (Smart 2007; Xing 2021; Jin 2025), so the concern is real and simply unresolved. This is one reason the unknown long-term safety matters.
This article is for research documentation and general information only. It is not medical advice, and TB-500 is not an approved treatment. Consult a qualified healthcare professional before making any health decision.
